Ying Cheng

49PUBLICATIONS
284CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapyPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Mar 14, 2026
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Yang Sun, Hongying Yang, Jing Wang

|Dec 18, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.

Yongmei Yin, Qingyuan Zhang, Tao Sun

|Nov 03, 2025
Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming.

Lin Tian, Hui Li, Heran Cui

|Oct 07, 2025
IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer.

Taofeek K Owonikoko, Lauren Byers, Ying Cheng

|Aug 19, 2025
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.

Shaodong Hong, Qiming Wang, Ying Cheng

|Aug 06, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

Chuanhua Zhao, Yanqiao Zhang, Gang Wang

Pageof 9

Frequent Collaborators

6 joint publications

Lin Wu

6 joint publications

Yi-Long Wu

3 joint publications

Suresh S Ramalingam

3 joint publications

Byoung Chul Cho